The market for cannabis products in the United States, both on the recreational and medicinal side is still in the early innings as each state wrangles with how to regulate cannabis products, what products to legalize, and how to tax them. The nascent market has been flooded with companies hoping to gain a foothold in a new industry, so finding winners in the field can be a challenge for investors. One company that is well-positioned to become a market leader is Pharmagreen Biotech (OTCQB: PHBI) which uses a proprietary process called Chibafreen to supply starter plants to licensed cannabis growers and hemp farmers. The company has several recent developments that can be viewed as positive catalysts for future growth.
A major business development milestone has been reached in the company’s partnership with Long Valley Farms to obtain nursery licenses which will enable the sale of live rosin and biomass products to cannabis manufacturers, distributors, and retailers. Pharmagreen Biotech is in the process of acquiring Long Valley Farms and is currently completing the funding required to finalize the transaction. Live rosin is an important avenue for future growth as the company estimates to receive revenues of $18,000 per day with minimal capital expenditures needed. The capability to serve all customers along the value chain will be important since firms that play in only one area, such as cultivation or retail have struggled to gain a dominant share of the market. Companies such as Pharmagreen Biotech that can build a vertically integrated model are poised to win since they can serve customers at all phases of the product lifecycle.
The company’s technology and greenhouse methods have use cases both in the cannabis industry and beyond. Pharmagreen Biotech uses proprietary technology to propagate starter plants that have reduced growing times and need less space than traditional growing methods. This allows the company to increase yearly growing cycles and grow more plants in existing spaces, allowing for increased yields, leading to increased revenues. This technology allows the company to grow and deliver many different strains of cannabis crop so it can provide products to meet customer demands which range from buzzed to creative to relaxed, and for customers looking to relieve stress and anxiety.
With the patchwork of Federal and state regulations and approvals still working through the regulatory process, it can be difficult for investors to figure out which cannabis companies are in a good position to become market leaders and which will fall by the wayside. Going right to the source, namely the young plants that will be turned into products across the cannabis spectrum seems like a good strategy for investors. Pharmagreen is leveraging technology to use less space to grow more plants, and efficiency is a strategy that has proven itself to be a winning one no matter what the industry.
Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.
All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated one thousand dollars cash for the creation and dissemination of this content by a third party Guerrilla Capital and Ryan Yanch.
This material does not represent a solicitation to buy or sell any securities. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.
The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.
Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
The post Pharmagreen Biotech (OTCQB: PHBI): Breaking Down the Catalysts for Future Growth appeared first on Spotlight Growth.
Source: SpotLight Growth Canabis
Pharmagreen Biotech (OTCQB: PHBI): Breaking Down the Catalysts for Future Growth
SpotLight Growth Canabis